SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (466)2/3/2009 9:35:53 PM
From: Biomaven1 Recommendation  Read Replies (1) of 508
 
>>much stronger placebo effect than IPF

Granted, but in both cases you are dealing with heterogeneous diseases with variable courses (over the length of a trial at least) and with some variability in endpoint measurement. (Of course depression trials are much larger which helps offset the placebo effect). Thus in both cases "stuff happens" that causes some trials to fail even though the drug might actually work.

But my main point was that ultimately the FDA doesn't seem to hold unsuccessful trials against you if you can come up with two successful trials. Here they have one successful trial and perhaps the Shinogi trial if the FDA will accept that, and certainly the potential for another successful trial at some point if the FDA turns them down now.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News